2.2.0.25truefalse40208 - Disclosure - ALLIANCES AND COLLABORATIONS (Pfizer) (Details)truefalseIn Millionsfalse1falsefalseUSDtruefalse{invest_InvestmentAxis} : Upfront Licensing and Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201012http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseUpfront Licensing and Milestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_UpfrontLicensingAndMilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2falsefalseUSDtruefalse{invest_InvestmentAxis} : Upfront Licensing and Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseUpfront Licensing and Milestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_UpfrontLicensingAndMilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3falsefalseUSDtruefalse{invest_InvestmentAxis} : Upfront Licensing and Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_200832http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseUpfront Licensing and Milestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_UpfrontLicensingAndMilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationspfizer
details1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse1falsefalseUSDtruefalse{invest_InvestmentAxis} : Upfront Licensing and Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201012http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseUpfront Licensing and Milestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_UpfrontLicensingAndMilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2falsefalseUSDtruefalse{invest_InvestmentAxis} : Upfront Licensing and Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseUpfront Licensing and Milestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_UpfrontLicensingAndMilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3falsefalseUSDtruefalse{invest_InvestmentAxis} : Upfront Licensing and Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_200832http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseUpfront Licensing and Milestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_UpfrontLicensingAndMilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse2false0bmy_AmortizationIncomeMilestonePaymentsbmyfalsecreditdurationAmount of previously reported deferred income that was recognized as other income during the period.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse3100000031falsetruefalsefalsefalse2truefalsefalse2800000028falsetruefalsefalsefalse3truefalsefalse2000000020falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of previously reported deferred income that was recognized as other income during the period.No authoritative reference available.falsefalse3false0bmy_DeferredIncomeLicensingAndMilestonePaymentsbmyfalsecreditdurationDeferred income is a liability related to a revenue or other income producing activity for which revenue or other income has...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse382000000382falsefalsefalsefalsefalse2truefalsefalse404000000404falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:mone
taryItemTypemonetaryDeferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized. Deferred income is recorded when consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.No authoritative reference available.falsefalse4false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationspfizerdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalseUSDtruefalse{invest_InvestmentAxis} : Research and Development Reimbursements [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010722http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseResearch and Development Reimbursements [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ResearchAndDevelopmentReimbursementsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{invest_InvestmentAxis} : Research and Development Reimbursements [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092229http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseResearch and Development Reimbursements [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ResearchAndDevelopmentReimbursementsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{invest_InvestmentAxis} : Research and Development Reimbursements [Member]
{us-gaap_BusinessAcquisitionAxis} : Pfizer [Member]
{dei_LegalEntityAxis} : Apixaban [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20089http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseResearch and Development Reimbursements [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ResearchAndDevelopmentReimbursementsMemberinvest_InvestmentAxisexplicitMemberfalsefalsePfizer [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_PfizerMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseApixaban [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ApixabanMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse5false0bmy_ReimbursementOfDevelopmentExpenseFromCollaborationsbmyfalsedebitdurationThe amount of development expenses reimbursed by the collaboration partner pursuant to t
he terms of the agreement that are...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse-190000000-190falsetruefalsefalsefalse2truefalsefalse-190000000-190falsetruefalsefalsefalse3truefalsefalse-159000000-159falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of development expenses reimbursed by the collaboration partner pursuant to the terms of the agreement that are netted in research and development expense.No authoritative reference available.falsefalse35ALLIANCES AND COLLABORATIONS (Pfizer) (Details) (Pfizer [Member], Apixaban [Member], USD $)MillionsUnKnownUnKnownUnKnownfalsetrue
